Xact Kapitalforvaltning AB bought a new position in Healthequity Inc (NASDAQ:HQY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,716 shares of the company’s stock, valued at approximately $220,000.
Several other institutional investors have also bought and sold shares of HQY. Catalyst Capital Advisors LLC bought a new stake in shares of Healthequity in the fourth quarter worth $149,000. Two Sigma Securities LLC bought a new stake in shares of Healthequity in the fourth quarter worth $208,000. Exane Derivatives grew its holdings in shares of Healthequity by 78.6% in the fourth quarter. Exane Derivatives now owns 4,682 shares of the company’s stock worth $218,000 after acquiring an additional 2,060 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of Healthequity in the third quarter worth $273,000. Finally, Signition LP bought a new stake in shares of Healthequity in the fourth quarter worth $348,000. 98.80% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on the company. Oppenheimer boosted their price target on Healthequity from $58.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, March 20th. ValuEngine raised Healthequity from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. JPMorgan Chase assumed coverage on Healthequity in a report on Tuesday. They set an “overweight” rating and a $69.00 price target for the company. Zacks Investment Research downgraded Healthequity from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $65.00 price objective on shares of Healthequity in a research report on Friday, March 23rd. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Healthequity currently has an average rating of “Buy” and a consensus price target of $68.30.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings data on Monday, March 19th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. Healthequity had a return on equity of 13.47% and a net margin of 20.64%. The firm had revenue of $60.44 million during the quarter, compared to analyst estimates of $58.46 million. sell-side analysts expect that Healthequity Inc will post 0.77 earnings per share for the current year.
In related news, VP Darcy G. Mott sold 9,500 shares of the firm’s stock in a transaction on Friday, April 20th. The stock was sold at an average price of $65.48, for a total value of $622,060.00. Following the completion of the transaction, the vice president now owns 108,500 shares in the company, valued at approximately $7,104,580. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jon Kessler sold 40,000 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $49.47, for a total value of $1,978,800.00. Following the sale, the insider now directly owns 485,000 shares in the company, valued at $23,992,950. The disclosure for this sale can be found here. Insiders sold a total of 750,831 shares of company stock valued at $40,586,678 in the last 90 days. 19.00% of the stock is currently owned by company insiders.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.